New study shows oral contraceptive may be effective in treating severe form of premenstrual syndrome

August 22, 2001

Unique hormone provides physical and emotional relief for women with severe PMS

Results from a double-blind, placebo-controlled study published in the current issue of the Journal of Women's Health and Gender-Based Medicine show that the combination of the progestin drospirenone with the estrogen ethinyl estradiol contained in the oral contraceptive Yasmin may be beneficial in treating premenstrual dysphoric disorder (PMDD), a severe form of premenstrual syndrome (PMS) that affects more than 3 million U.S. women.

PMDD, a distinct medical condition characterized by severe monthly mood swings and physical symptoms that interfere with everyday life, has a noted impact on a woman's relationship with her family and friends. Cyclic symptoms of depressed mood, anxiety, irritability, breast tenderness and bloating go far beyond those associated with typical or common PMS.

PMDD sufferers experience symptoms that occur during the week or two before the menstrual period and disappear within four days of the onset of menstruation. Definitive cases include symptoms documented daily for at least two consecutive menstrual cycles.

"While oral contraceptives are among the most widely prescribed products available, they are largely understudied for the treatment of PMS and PMDD," said Dr. Andrea J. Rapkin, an author of the study and UCLA professor of obstetrics and gynecology. "The results of our study suggest that Yasmin, with its unique combination of drospirenone and ethinyl estradiol, holds promise for reducing PMDD symptoms and its disruptive and impairing affect on women's lives."

Drospirenone is different from the progestins currently available in other oral contraceptives. Drospirenone is chemically related to spironolactone, a diuretic or "water pill" widely used by gynecologists to treat fluid retention for many women. Similarly to spironolactone, drospirenone influences the regulation of water and sodium levels in the body.

Animal studies show that Yasmin also demonstrates antiandrogenic (anti-male hormone) properties that may result in a favorable effect on mild-to-moderate acne, unwanted facial hair growth and irritability.

Researchers caution that Yasmin may not be appropriate for women with kidney, liver or adrenal disease because it may increase potassium levels. Patients taking drugs that could increase potassium should consult their health-care professional before taking Yasmin.

"It is important to educate women about PMDD and let them know that they don't have to tolerate debilitating symptoms as an inevitable consequence of their menstrual cycle," said Dr. Ellen Freeman, lead author of the study and professor in the Department of Obstetrics and Gynecology at the University of Pennsylvania Medical Center. "Women should know that what they're experiencing is the result of a legitimate medical condition and that there is effective treatment available to them."

Eighty-two women aged 18-40 completed the three-month study, where the Yasmin users showed greater improvement than the placebo group. Yasmin was well tolerated, with adverse reactions typical of those associated with oral contraceptive use.

Researchers said further evaluation of Yasmin in larger placebo-controlled studies is needed to determine the extent of its effectiveness for the treatment of PMDD.

This study was sponsored by Berlex Laboratories Inc., which makes Yasmin.

UCLA's Department of Obstetrics and Gynecology offers a full range of women's health-related services such as those for high-risk pregnancy, gynecologic cancer, reproductive endocrinology and infertility. UCLA's obstetrics-gynecology department ranks fourth in the nation and UCLA Medical Center ranks as the best hospital in the Western United States for the 12th consecutive year, according to this year's U.S. News & World Report's annual guide to "America's best hospitals."
-end-
For more information or to make an appointment, call 800-UCLA-MD1.

Maya Studzinski, mstudzinksi@porternovelli.com
Porter Novelli
212-601-8244

University of California - Los Angeles

Related Menstrual Cycle Articles from Brightsurf:

Menstrual dysfunction is more common among young athletes than among non-athletes
Menstrual dysfunction is more prevalent in young Finnish athletes than it is among non-athletes of a similar age, but athletes experience less body weight dissatisfaction than non-athletes do.

Irregular and long menstrual cycles linked to greater risk of early death
Irregular and long menstrual cycles in adolescence and adulthood are associated with a greater risk of early death (before age 70), finds a study published by The BMJ today.

Understanding the 'deep-carbon cycle'
New geologic findings about the makeup of the Earth's mantle are helping scientists better understand long-term climate stability andĀ even how seismic waves move through the planet's layers.

Seizures during menstrual cycle linked to drug-resistant epilepsy
More frequent seizures during the menstrual cycle in women with genetic generalized epilepsy have been linked for the first time to drug-resistant epilepsy, when anti-seizure medications don't work, according to a Rutgers coauthored study that may help lead to tailored treatments.

Busting Up the Infection Cycle of Hepatitis B
Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the ''spiky ball'' that encloses its genetic blueprint.

IUDs successfully manage menstrual pain in adolescents with disabilities
Adolescents and young women with disabilities can stop periods and get relief from distressing menstrual symptoms with IUDs, in the largest study in this population to date.

Consuming extra calories can help exercising women avoid menstrual disorders
Exercising women who struggle to consume enough calories and have menstrual disorders can simply increase their food intake to recover their menstrual cycle, according to a study accepted for presentation at ENDO 2020, the Endocrine Society's annual meeting, and publication in the Journal of the Endocrine Society.

Oral hormone-blocking drug may help with heavy menstrual bleeding
In women with uterine fibroids, the drug elagolix suppresses ovarian hormone production and prevents heavy menstrual bleeding.

Blood tests can predict timing of final menstrual period
Blood tests could replace menstrual periods as a gauge for when a women is nearing menopause, according to new research published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

How bacteria control their cell cycle
Researchers at the Biozentrum of the University have demonstrated how bacteria coordinate cell division with the replication of their genetic material.

Read More: Menstrual Cycle News and Menstrual Cycle Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.